U · A
Unknown Author
January 24, 2026
Latham & Watkins Represents Akebia Therapeutics in Term Loan Financing
1 min
AI-made summary
- Akebia Therapeutics, Inc
- has closed a loan facility with funds and accounts managed by BlackRock, providing the company with up to US$55 million in borrowing capacity across three tranches
- Latham & Watkins LLP represented Akebia in the transaction, with a finance team led by partner Jennifer Kent and associates Trevor Church, Jake Goodman, and Jack Gillen, and additional corporate advice from Wesley Holmes and Samuel Niles.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to US$55 million of borrowing capacity available in three tranches. Latham & Watkins LLP represented Akebia Therapeutics in the transaction with a finance team led by Washington, D.C. partner Jennifer Kent, with associates Trevor Church, Jake Goodman, and Jack Gillen. Advice was also provided on corporate matters by Boston partner Wesley Holmes, with New York associate Samuel Niles.~~
U
Article Author
Unknown Author
The Sponsor
